How AI is applied across API Evangelist and APIs.io. Read my AI disclosure →

JNT-517, a first-in-class SLC6A19 inhibitor, reduces plasma phenylalanine levels in subjects with phenylketonuria in a Phase 1/2 study

calendar_today September 4, 2024 person Sarah Bozaan domain jnana-therapeutics

The post JNT-517, a first-in-class SLC6A19 inhibitor, reduces plasma phenylalanine levels in subjects with phenylketonuria in a Phase 1/2 study appeared first on Jnana Therapeutics .

open_in_new Read original post

Discovery

Learnings

Guidance

Toolbox

Alignment

API Evangelist LLC

JNT-517, a first-in-class SLC6A19 inhibitor, reduces plasma phenylalanine levels in subjects with phenylketonuria in a Phase 1/2 study